New target therapies in advanced pancreatic cancerS Cascinu
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Ancona, Italy
Ann Oncol 17:v148-52. 2006
..This review highlights recent findings in the treatment of pancreatic cancer by using these novel therapeutic approaches...
Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trialStefano Cascinu
Polytechnic University of Marche Riuniti Hospital Umberto I GM Lancisi G Salesi of Ancona, 60020 Ancona, Italy
Lancet Oncol 9:39-44. 2008
..The aim of this study was to assess the activity and feasibility of a combination of cetuximab with gemcitabine and cisplatin compared with use of gemcitabine and cisplatin alone for the treatment of advanced pancreatic cancer...
Gastrointestinal cancer refractory to chemotherapy: a role for octreotide?S Cascinu
Section of Experimental Oncology, Division of Medical Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
Chemotherapy 47:127-33. 2001
....
Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trialStefano Cascinu
Department of Medical Oncology, Azienda Ospedaliera Universitaria di Parma, Via Gramsci 14, 43100 Parma, Italy
J Clin Oncol 20:3478-83. 2002
..We performed a randomized, double-blind, placebo-controlled trial to assess the efficacy of glutathione (GSH) in the prevention of oxaliplatin-induced neurotoxicity...
P-CHOP: cisplatin (P) added to the standard CHOP regimen as first-line treatment for aggressive non-Hodgkin lymphoma: a single-institution phase II studyGiorgio Cocconi
Medical Oncology Division, Azienda Ospedaliera Universitaria, Parma, Italy
Am J Clin Oncol 26:535-42. 2003
..It is feasible and warrants further research, which would ideally take the form of a randomized comparison of P-CHOP and CHOP, possibly with the addition of rituximab in both arms...
Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysisMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020, Ancona, Italy
J Exp Clin Cancer Res 29:164. 2010
..In our experience, lipiodol TACE showed a better OS and TTP over pTACE, without difference in toxicity profile and RR. Among the staging systems analyzed only the Okuda stage seemed able to reliably predict patients outcome...
Epidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysisMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
BMC Cancer 9:303. 2009
..Based on these findings we investigated the correlation between both FISH and CISH EGFR GCN and clinical outcome in K-RAS wild-type colorectal cancer treated with irinotecan-cetuximab...
Potential role and chronology of abnormal expression of the Deleted in Colon Cancer (DCC) and the p53 proteins in the development of gastric cancerF Graziano
Medical Oncology Unit, Hospital of Urbino, Italy
BMC Cancer 1:9. 2001
..According to this hypothesis, we investigated the p53 and the DCC proteins expression in different stages of gastric carcinomas...
Molecular markers predictive of response to chemotherapy in gastrointestinal tumorsV Catalano
Department of Medical Oncology, Azienda Ospedaliera Ospedale S Salvatore, 61100, Pesaro, Italy
Crit Rev Oncol Hematol 38:93-104. 2001
..Available data are promising, but most of them arise from retrospective and small studies. Well designed, prospective trials are warranted to change the target approach from a general to an individual treatment strategy...
Survival and quality of life in gastrointestinal tumors: two different end points?S Cascinu
Medical Department, Azienda Ospedaliera di Parma, Italy
Ann Oncol 12:S31-6. 2001
..In gastrointestinal tumors, the traditional end point of medical treatment was represented mainly by survival. In the last few years, however, there has been an increasing awareness about the role of quality of life...
Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: relationships with tumor recurrence and resistance to adjuvant chemotherapyS Cascinu
Medical Oncology, Hospital of Parma, Italy
Ann Oncol 12:239-44. 2001
..The combined analysis of SPF/VEGF was studied for predictivity of recurrent disease, the TS quantitation was related to the efficacy of fluorouracil-based adjuvant chemotherapy...
Infusional 5-fluorouracil, cisplatin and mitomycin C in advanced gastric cancer: a low cost effective regimenS Cascinu
Department of Medical Oncology, V le Gramsci 14, 43100 Parma, Italy
Br J Cancer 86:213-7. 2002
..Because of its low cost it may be suggested for patients not enrolled into clinical trials...
An analysis of p53, BAX and vascular endothelial growth factor expression in node-positive rectal cancer. Relationships with tumour recurrence and event-free survival of patients treated with adjuvant chemoradiationS Cascinu
Division of Medical Oncology, Hospital of Parma, Italy
Br J Cancer 86:744-9. 2002
..In this study, vascular endothelial growth factor and p53 expressions correlated with recurrent disease, pattern of relapse and poor event-free survival...
Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD)S Cascinu
Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
Ann Oncol 13:716-20. 2002
..To evaluate the safety and efficacy of the novel raltitrexed/oxaliplatin combination (TOMOX) as first-line chemotherapy for patients with advanced colorectal cancer...
Differences of vascular endothelial growth factor (VEGF) expression between liver and abdominal metastases from colon cancer. Implications for the treatment with VEGF inhibitorsS Cascinu
Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
Clin Exp Metastasis 18:651-5. 2000
..Evidence is supported that the VEGF expression may be different between colon cancer metastatic sites. The efficacy of anti-VEGF treatments may depend on the VEGF expression status, and this finding deserves further investigation...
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trialStefano Cascinu
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
Cancer Chemother Pharmacol 68:37-43. 2011
..With the aim to maintain efficacy while reducing toxicity, we compared the activity and safety of a combination of 5-FU, cisplatin and pegylated liposomal doxorubicin with a combination of 5-FU, cisplatin and mitomycin-C...
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trialStefano Cascinu
Universita Politecnica delle Marche, Via Conca 60020 Ancona, Italy
J Natl Cancer Inst 99:601-7. 2007
....
COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatinStefano Cascinu
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda ospedaliera Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
Am J Clin Oncol 30:526-30. 2007
..We investigated the role of COX-2 and NF-KB expression in relation to the use of a COX-2 inhibitor (celecoxib) associated to gemcitabine and oxaliplatin in pancreatic cancer...
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activationS Cascinu
Department of Medical Oncology, Universita Politecnica delle Marche, Ancona, Italy
Br J Cancer 98:71-6. 2008
..Furthermore, while NF-kB activation seems to predict resistance to chemotherapy as demonstrated 'in vitro' models, gefitinib does not overcome this mechanism of resistance, as reported for cetuximab...
High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive TractS Cascinu
Clinica di Oncologia, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, Via Conca, Ancona 60020, Italy
Br J Cancer 90:1521-5. 2004
..The median and 4-year survival for the whole group was 17 months and 31%, respectively. The median survival was 12 months for inoperable patients and it was not reached in resected patients...
Gastric cancer treatment: a systematic reviewRossana Berardi
Clinica di Oncologia Medica, Università Politecnica delle Marche Azienda Ospedaliera Umberto I, 60020 Ancona, Italy
Oncol Rep 11:911-6. 2004
..This review will focus on the several treatment modalities available for gastric cancer patients: surgery, adjuvant, neoadjuvant and palliative chemotherapy as well as new target agents...
Pain and its treatment in hospitalized patients with metastatic cancerStefano Cascinu
Medical Oncology, University Hospital of Parma, Parma, Italy
Support Care Cancer 11:587-92. 2003
..The aim of this prospective study was to assess the quality of pain management hospitalized cancer patients...
Inhibition of vascular endothelial growth factor by octreotide in colorectal cancer patientsS Cascinu
Sezione di Oncologia Sperimentale, Azienda Ospedaliera Ospedale S Salvatore, 61100 Pesaro, Italy
Cancer Invest 19:8-12. 2001
....
Immunohistochemical determination of p53 protein does not predict clinical response in advanced colorectal cancer with low thymidylate synthase expression receiving a bolus 5-fluorouracil-leucovorin combinationS Cascinu
Department of Medical Oncology, Azienda Ospedaliera di Parma, Italy
Ann Oncol 11:1053-6. 2000
..We assessed the hypothesis that a compromised p53 function could account for the non response of colon cancer patients with low thymidylate synthase (TS) expression receiving a bolus 5-fluorouracil (5-FU) leucovorin (LV) combination...
A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu
Medical Oncology, Azienda Ospedaliera di Parma, Italy
Ann Oncol 11:1309-11. 2000
..Laboratory evidences suggest the possibility that an infusion rate of 10 mg/m2/min may be more effective than the standard 30-min infusion of Gemcitabine (GEM)...
Resection-line involvement in gastric cancer patients undergoing curative resections: implications for clinical managementS Cascinu
Division of Medical Oncology, Azienda Ospedaliera Ospedale S Salvatore, Pesaro, Italy
Jpn J Clin Oncol 29:291-3. 1999
..Resection-line involvement has been suggested as an important prognostic factor for gastric cancer...
Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancerS Cascinu
Istituto di Oncologia, Universita degli Studi di Messina, Italy
Clin Cancer Res 6:2803-7. 2000
..66 +/- 0.17; P = 0.0001). VEGF may be used in a clinical setting to identify patients at high risk for relapse who may benefit from adjuvant treatment including new therapeutic strategies such as monoclonal antibody neutralizing VEGF...
Effects of calcium and vitamin supplementation on colon cell proliferation in colorectal cancerS Cascinu
Section of Experimental Oncology, Azienda Ospedaliera S Salvatore, Pesaro, Italy
Cancer Invest 18:411-6. 2000
..Furthermore, this study suggests the need for extreme caution in the interpretation and publication of studies on chemoprotectants in colon cancer without a control group...
A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu
Department of Medical Oncology, University of Messina, Italy
Ann Oncol 10:1377-9. 1999
..We determined the maximum tolerable dose of docetaxel combined with a weekly fixed dose of gemcitabine and assessed the activity of this combination in advanced pancreatic cancer...
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerS Cascinu
Division of Medical Oncology, Azienda Ospedale di Parma, Italy
Br J Cancer 84:470-4. 2001
..The sequential application of docetaxel after PELF chemotherapy gained major objective responses with manageable toxicity. This strategy is worth of further investigation in the setting of palliative or neoadjuvant chemotherapy...
Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu
Department of Medical Oncology, Ancona, Italy
Br J Cancer 79:491-4. 1999
..7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer...
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patientsM Scartozzi
Clinica di Oncologia Medica, , Ancona, Italy
Oncology 68:212-6. 2005
..04). CONCLUSIONS: These data suggest that reintroduction of 5-FU could increase irinotecan and oxaliplatin activity in patients progressing during a 5-FU-based first-line chemotherapy...
Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu
Division of Medical Oncology, S Salvatore Hospital, Pesaro, Italy
Br J Cancer 78:390-3. 1998
..This weekly intensive regimen enabled resection in half of previously inoperable tumours with a moderate toxicity. It can be offered to patients with locally advanced unresectable gastric cancer to obtain curative resection...
Lymphatic, blood vessel and perineural invasion identifies early-stage high-risk radically resected gastric cancer patientsM Scartozzi
The Departments of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, , Via Conca, 60020 Ancona, Italy
Br J Cancer 95:445-9. 2006
....
Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracilC Aschele
Department of Medical Oncology, EO Ospedali Galliera, Genoa, Italy
Ann Oncol 13:1882-92. 2002
....
Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumabM Scartozzi
Clinic of Medical Oncology, Polytechnic University of the Marche Region, Riuniti Hospital, Ancona, Italy
Ann Oncol 20:227-30. 2009
....
A pilot clinical trial of postoperative intensive weekly chemotherapy using cisplatin, epi-doxorubicin, 5-fluorouracil, 6S-leucovorin, glutathione and filgrastim in patients with resected gastric cancerF Graziano
Section of Experimental Oncology, Ospedale S. Salvatore, Pesaro, Italy
Tumori 84:368-71. 1998
..These data, together with recent results in advanced disease, make this approach of interest for the development of new programs of adjuvant therapy in this setting...
Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximabM Scartozzi
Department of Medical Oncology, United Hospitals, and Postgraduate School in Medical Oncology, University of Ancona, Ancona, Italy
Ann Oncol 23:1706-12. 2012
....
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combinationS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
J Chemother 4:46-9. 1992
..We conclude that salvage chemotherapy is not recommended in colorectal cancer after 5-fluorouracil/leucovorin treatment even in patients with generally considered favorable characteristics for response to chemotherapy...
Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factorsS Cascinu
Azienda Ospedaliera di Parma, Parma, Italy
Ann Oncol 14:ii25-9. 2003
....
Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patientsM Scartozzi
Department of Medical Oncology, , Ancona, Italy
Br J Cancer 92:1051-4. 2005
..An inadequate lymph nodes resection can affect survival and result in a higher incidence of local relapse, making the latter group of patients optimal candidates for adjuvant chemoradiation...
Phase II study of cetuximab in combination with cisplatin and docetaxel in patients with untreated advanced gastric or gastro-oesophageal junction adenocarcinoma (DOCETUX study)C Pinto
Department of Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
Br J Cancer 101:1261-8. 2009
..The purpose of this phase II study was to evaluate the activity and safety of cetuximab combined with cisplatin and docetaxel as a first-line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma...
Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trialD Santini
Medical Oncology, University Campus Bio Medico, Rome, Italy
BMC Cancer 6:125. 2006
..The secondary objective was to measure the time to disease progression and the survival time...
A pilot clinical trial of surgical adjuvant treatment with high-dose 6S-leucovorin/5-fluorouracil and radiation therapy for high-risk rectal carcinomaS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Tumori 80:335-8. 1994
..The advantage of this combination, in terms of recurrence rate and survival with respect to 5FU/radiotherapy alone, will have to be evaluated in randomized trials...
A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)S Cascinu
Division of Medical Oncology, Azienda Ospedaliera Ospedale S Salvatore, Pesaro, Italy
Br J Cancer 80:1595-8. 1999
....
Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapyF Graziano
University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
Expert Rev Anticancer Ther 1:247-57. 2001
..High-risk patients could be the target for future adjuvant chemotherapy trials and one or more of these markers may identify prognostic subgroups with the same TNM stage category...
Pre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patientsM Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, Ancona, Italy
Br J Cancer 106:799-804. 2012
..We explored the role of pre-treatment LDH serum levels in colorectal cancer patients receiving first-line bevacizumab...
Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patientsC Braconi
Centro Regionale di Genetica Oncologica Oncologia Medica, Universita Politecnica delle Marche, Ancona, Italy
Ann Oncol 19:1293-8. 2008
..The expression of the insulin-like growth factor (IGF) system has never been studied in gastrointestinal stromal tumors (GISTs)...
Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patientsM Scartozzi
Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 60020 Ancona, Italy
Br J Cancer 104:1786-90. 2011
..The primary aim of our study was to verify a possible correlation between EGFR gene promoter methylation and clinical outcome in metastatic colorectal cancer patients receiving chemotherapy with irinotecan and cetuximab...
Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combinationS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
J Chemother 4:185-8. 1992
..Because of this we think that this regimen cannot be recommended for the treatment of elderly advanced gastric cancer patients...
Pre-operative treatment modalities in gastric cancer patientsM Scartozzi
Clinica di Oncologia Medica, , via Conca 60 020, Ancona, Italy
Ann Oncol 16:iv106-109. 2005
5-Fluorouracil dose intensity increase in 5-fluorouracil and leucovorin combination: results of a phase II studyS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
J Chemother 3:51-4. 1991
..Furthermore, in an analysis of data from the literature we did not find any difference in response rate in relation to dose intensity in the 5-fluorouracil/leucovorin combination...
Intensive weekly chemotherapy for elderly gastric cancer patients, using 5-fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin and glutathione with the support of G-CSFS Cascinu
Servizio di Oncologia Medica, Ospedali Riuniti, Pesaro, Italy
Tumori 81:32-5. 1995
..CONCLUSIONS: This regimen appears feasible also in elderly gastric cancer patients and, because of its activity, suitable for further studies...
Feasibility of preoperative chemoradiation in rectal cancer patients aged 70 and olderG Mantello
Dept of Oncology and Radiotherapy, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
J Exp Clin Cancer Res 24:541-6. 2005
..In conclusion, concomitant radiochemotherapy 5FU based is safe in rectal cancer patients aged > or = 70 with a good tumour downstaging (61% of patients) and excellent feasibility. No treatment related death was observed...
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)C Pinto
Medical Oncology, S Orsola Malpighi Hospital, Bologna, Italy
Ann Oncol 18:510-7. 2007
..The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma...
Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancerS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Br J Cancer 69:392-3. 1994
....
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patientsM Scartozzi
Department of Medical Oncology, United Hospitals, Polytechnic Marche University, Ancona, Italy
Ann Oncol 22:897-902. 2011
..Preclinical studies suggested that integrins are relevant for gastric cancer diffusion. We investigated integrins polymorphisms role in determining peritoneal carcinosis or hematogenous metastases in radically resected gastric cancer...
A pilot clinical trial of postoperative adjuvant intraperitoneal cisplatin, 5-fluorouracil, 6S-leucovorin and interferon alpha 2b in patients with resected gastric cancerS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Tumori 79:331-5. 1993
..These data make this approach interesting for the development of new programs of adjuvant therapy of high-risk gastric cancer...
Chemotherapy for locally advanced and metastatic gastric cancer: state of the art and future perspectivesA Bittoni
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
Eur Rev Med Pharmacol Sci 14:309-14. 2010
..In advanced disease, major improvements of the last years are represented by the introduction of oral fluoropyrimidines and drugs such as docetaxel or irinotecan and the demonstration of efficacy of the anti-HER2 agent trastuzumab...
Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment optionsM Scartozzi
Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Via Conca 60020, Ancona, Italy
Br J Cancer 97:92-7. 2007
..EGFR downstream signalling pathway can be overactivated even in the absence of EGFR expression in a considerable proportion of patients...
Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot studyS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Br J Cancer 67:156-8. 1993
..Haemoglobin increases occurred despite continuation of cisplatin chemotherapy. In conclusion subcutaneous low dose of erythropoietin seems to be effective and safe in the treatment of cisplatin-induced anaemia...
Elderly patients with advanced colorectal cancer: tolerability and activity of chemotherapyRossana Berardi
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Unmberto 1, G M Lancisi, G Salesi, Ancona, Italy
Tumori 91:463-6. 2005
..The aim of the present study was to analyze the tolerability and activity of chemotherapy with 5-fluorouracil plus oxaliplatin or CPT-11 in elderly patients with advanced colorectal cancer...
Different doses of pamidronate in patients with painful osteolytic bone metastasesS Cascinu
Sezione di Oncologia Sperimentale, Azienda Ospedaliera Ospedale S Salvatore, Pesaro, Italy
Support Care Cancer 6:139-43. 1998
..In conclusion, our results seem to confirm the utility of higher doses of pamidronate in patients with painful bone metastases, because of the faster symptom relief achieved...
KIT and PDGFRalpha mutations in 104 patients with gastrointestinal stromal tumors (GISTs): a population-based studyC Braconi
Centro Regionale di Genetica Oncologica, Oncologia Medica, Ancona, Italy
Ann Oncol 19:706-10. 2008
..The prognostic significance of KIT or platelet-derived growth factor receptor alpha (PDGFRalpha) mutations in gastrointestinal stromal tumors (GISTs) is still controversial...
A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapyS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Br J Cancer 71:97-101. 1995
..Additional studies will be needed to confirm these results and to clarify other questions about dose and schedule of octreotide...
Chemotherapy for advanced pancreatic cancer: the history is changingF Graziano
Sezione di Oncologia Sperimentale, Azienda Ospedaliera Ospedale S. Salvatore, Pesaro, Italy
Tumori 84:308-11. 1998
..The results are far from conclusive, and only partially satisfying but they represent a step forward...
Multicentric, randomized phase III trial of two different adjuvant chemotherapy regimens plus three versus twelve months of trastuzumab in patients with HER2- positive breast cancer (Short-HER Trial; NCT00629278)Valentina Guarneri
Division of Medical Oncology, Department of Oncology and Hematology, University Hospital, Modena, Italy
Clin Breast Cancer 8:453-6. 2008
..The primary objective is disease-free survival...
Prospective multicenter study of combined treatment with chemotherapy and radiotherapy in breast cancer women with the rare clinical scenario of ipsilateral supraclavicular node recurrence without distant metastasesStefano Pergolizzi
Department of Radiological Science, University of Messina, Messina, Italy
Int J Radiat Oncol Biol Phys 65:25-32. 2006
....
Capecitabine and mitomycin C may be an effective treatment option for third-line chemotherapy in advanced colorectal cancerMario Scartozzi
Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, , Ancona, Italy
Tumori 92:384-8. 2006
..CONCLUSIONS: The combination of capecitabine and mitomycin C could represent an effective and manageable treatment option for colorectal cancer patients failing previous chemotherapy regimens...
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodesNicola Battelli
Clinica di Oncologia Medica, Dipartimento di Oncologia e Radioterapia, Ospedali Riuniti Umberto I G M Lancisi G Salesi, Polo Ospedale Università, Ancona, Italy
Am J Clin Oncol 29:380-4. 2006
....
Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapyMario Scartozzi
Clinica di Oncologia Medica and Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Universita Politecnica delle Marche, Ancona, Italy
J Clin Oncol 25:3930-5. 2007
..The aim of our analysis was to investigate a correlation between NF-kB expression, response rate, time to progression, and survival in advanced colorectal cancer patients receiving cetuximab and irinotecan...
Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patientsMario Scartozzi
Clinica di Oncologia Medica, , Ancona, Italy
Lung Cancer 53:103-9. 2006
..031) and 10 months versus 9 months for hMSH2 (p=0.8330). Both the difference in response rate and in median survival observed according to MMR status seem to confirm what has been suggested by preclinical studies...
[The DUR studies: colon cancer adjuvants]Stefano Cascinu
Clinica di Oncologia Medica, , Ancona
Suppl Tumori 3:S88. 2004
Adjuvant chemotherapy in gastric cancer. The Italian experience and review of the literatureRossana Berardi
Medical Oncology Department, University of Ancona, Azienda Ospedaliera Umberto I, Ancona, Italy
Suppl Tumori 2:S45-7. 2003
..CONCLUSIONS: Further studies are warranted to identify more satisfactory strategies as well as to identify patients who are more likely to benefit from an adjuvant treatment...
Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodiesMario Scartozzi
Clinica di Oncologia Medica, Istituto di Anatomia Patologica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
J Clin Oncol 22:4772-8. 2004
....
Locally advanced rectal cancer patients receiving radio-chemotherapy: a novel clinical-pathologic score correlates with global outcomeRossana Berardi
Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Ancona, Italy
Int J Radiat Oncol Biol Phys 75:1437-43. 2009
..To determine the importance of downstaging of locally advanced rectal cancer after neoadjuvant treatment...
Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases studyD Santini
Department of Medical Oncology, University Campus Bio Medico, Rome, Italy
Ann Oncol 23:2072-7. 2012
..Data are limited regarding bone metastases from colorectal cancer (CRC). The objective of this study was to survey the natural history of bone metastasis in CRC...
Twice-daily dosing of temozolomide in combination with fotemustine for the treatment of patients with refractory glioblastomaM Santoni
Department of Medical Oncology, Polytechnic University of the Marche Region, Azienda Ospedaliero Universitaria, Ospedali Riuniti Umberto I GM Lancisi and G Salesi, Ancona, Italy
Anticancer Res 32:1099-101. 2012
..Results indicate that our temozolomide -FTM combined schedule is not effective, although well tolerated, in non responsive patients with GBM. Further strategies are required to improve the outcome of these patients...
Weekly gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase II studyP Lippe
Department of Medical Oncology, Ancona University, Italy
Ann Oncol 10:217-21. 1999
..However, the optimal schedule for administration of the two drugs has not yet been determined. In this study we evaluated the activity and toxicity of a weekly gemcitabine and cisplatin schedule...
Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancerMario Scartozzi
AO Ospedali Riuniti Università Politecnica delle Marche, Clinica di Oncologia Medica, Via Conca, 60020, Ancona, Italy
Curr Opin Mol Ther 12:361-71. 2010
..Although preliminary results appear promising, only future clinical and translational data will clarify the best clinical setting and treatment combinations for the optimal use of dalotuzumab in clinical practice...
Compliance and outcomes in locally advanced head and neck cancer patients treated with alternating chemo-radiotherapy in clinical practiceVittorio Franciosi
Division of Medical Oncology, University Hospital of Parma, Italy
Tumori 89:20-5. 2003
..To evaluate the feasibility in clinical practice of alternating chemo-radiotherapy in locally advanced head and neck cancer patients...
Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patientsVittorio Franciosi
Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
Lung Cancer 41:101-6. 2003
..The aims of this phase II study were to evaluate the response rate and toxicity of the gemcitabine-oxaliplatin combination in patients with advanced NSCLC and poor prognosis...
Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecanMario Scartozzi
Department of Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Ancona, Italy
Int J Cancer 127:1941-7. 2010
..Combined IGF-1 and K-RAS analysis may represent an effective strategy for a better selection of responding colorectal cancer patients...
Pancreatic cancer: progress in cancer therapyChiara Pierantoni
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, Lancisi, Salesi, Ancona, Italy
Crit Rev Oncol Hematol 67:27-38. 2008
..New treatment strategies and a more careful evaluation of innovative therapies are clearly needed for this disease. In this review we will focus on treatment strategies both in resectable and advanced pancreatic cancer...
The role of levamisole in the adjuvant treatment of stage III colon cancer patients: a randomized trial of 5-fluorouracil and levamisole versus 5-fluorouracil aloneStefano Cascinu
Clinica di Oncologia Medica, , Ospedale di Torrette, 60020 Ancona, Italy
Cancer Invest 21:701-7. 2003
..The addition of Lev to 5FU does not seem to be relevant for the clinical activity of this adjuvant regimen, whereas toxicity related to Lev should be considered when an adjuvant treatment for stage III colon cancer patients is proposed...
Epidermal growth factor receptor: a promising therapeutic target for colorectal cancerMario Scartozzi
Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti Università Politecnica delle Marche, Ancona and Istituto di Anatomia Patologica, Universita Politecnica delle Marche, Ancona, Italy
Anal Quant Cytol Histol 28:61-8. 2006
..Moreover, the biological selection of colorectal tumors more likely to benefit from this treatment approach is still to be defined...
New frontiers in the neoadjuvant therapy of pancreatic adenocarcinoma: apart from therapeutical protocolsRossana Berardi
, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I, GM Lancisi and G Salesi di Ancona, Ancona, Italy
JOP 6:118-21. 2005
Mucinous rectal adenocarcinoma can be associated to tumor downstaging after preoperative chemoradiotherapyFilippo Grillo-Ruggieri
Dipartimento di Oncologia e Radioterapia Generale, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy
Dis Colon Rectum 50:1594-603. 2007
..The aim of this study was to evaluate downstaging as primary end point, and progression-free survival and overall survival as secondary end points, in rectal adenocarcinoma patients treated with preoperative chemoradiation...
[Paraneoplastic syndromes: a review]R Berardi
Clinica di Oncologia Medica, Azienda Ospedaliero, Universita Politecnica delle Marche, Ancona, Italia
Clin Ter 156:281-8. 2005
..This review discusses all the main paraneoplastic syndromes, focusing mainly on their clinical aspect and reminding the most commonly associated cancers...
Perioperative anemia and blood transfusions as prognostic factors in patients undergoing resection for non-small cell lung cancersR Berardi
Clinica di Oncologia Medica, Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I Lancisi Salesi, Ancona, Italy
Lung Cancer 49:371-6. 2005
..Our results suggested that anemia could represent an important prognostic factor in resected NSCLC and correction of anemia in the perioperative setting does not reduce the risk of relapse...
Chemotherapy for advanced gastric cancer: across the years for a standard of careMario Scartozzi
Universita Politecnica delle Marche, Department of Clinica di Oncologia Medica, Azienda Ospedaliera Ospedali Riuniti, Ancona, Italy
Expert Opin Pharmacother 8:797-808. 2007
..The objective of this article is to review the present literature available on major Phase II - III clinical trials, in which patients suffering from advanced gastric cancer were treated with cytotoxic chemotherapy...
Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature reviewRossana Berardi
Clinica di Oncologia Medica, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Italy
Crit Rev Oncol Hematol 69:223-36. 2009
..We extensively reviewed the published scientific literature on this topic in order to investigate the clinical and genetic profiling underlying lung cancer in women and to use this information as a tool for medical therapy...
Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectivesMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Ancona, Universita Politecnica delle Marche, Ancona, Italy
Cancer Treat Rev 35:451-62. 2009
..This systematic review will analyse available data about these factors with the aim to constitute a starting point for future research...
Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategyMario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti, Universita Politecnica delle Marche, Via Conca, 71, Ancona, 60020, Italy
Curr Oncol Rep 12:175-85. 2010
..Along with new effective therapeutic opportunities, better clinical and molecularly driven patient selection will represent the cornerstone of the global care for these patients...
Locally advanced rectal cancer: from molecular profiling to clinical practice. A literature review: Part 2Rossana Berardi
Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I, GM Lancisi G Salesi di Ancona, Medical Oncology Unit, 60020 Ancona, Italy
Expert Opin Pharmacother 10:2467-78. 2009
..The present review analyzes the new molecular targets that could be involved in predicting response and prognosis...
A cost-benefit analysis of chemotherapy for gastric cancerEva Galizia
Univeritaria Ospedali Riuniti Umberto I, Salesi, Lancisi di Ancona, Italy
Expert Opin Pharmacother 5:2109-14. 2004
..The aim of this paper is to review the results of the main studies regarding the relationship between the cost of chemotherapy and its effectiveness in advanced gastric and gastrointestinal cancer patients...
Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?Mario Scartozzi
Clinica di Oncologia Medica, AO Ospedali Riuniti Università Politecnica delle Marche, Via Conca, 6020 Ancona, Italy
Lung Cancer 68:433-7. 2010
....
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based studyAntonino Musolino
Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
Tumori 91:505-12. 2005
..To evaluate the clinical features of breast cancer patients with genetic susceptibility to this disease and to investigate the contribution of BRCA1 germline mutations to the phenotype of these tumors...
Anti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practiceMario Scartozzi
Azienda Ospedaliera Ospedali Riuniti-Universita, Clinica di Oncologia Medica, Politecnica delle Marche, Via Conca 60020, Ancona, Italy
Expert Opin Ther Targets 10:281-7. 2006
..Moreover, the biological selection of colorectal tumours most likely to benefit from this treatment approach is still to be defined...
Experience with intrapleural natural beta interferon in the treatment of malignant pleural effusionsS Cascinu
Servizio di Oncologia, Ospedali Riuniti, Pesaro, Italy
Tumori 77:237-8. 1991
..In our opinion, this schedule cannot be recommended for routine use...
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1Rossana Berardi
Universita Politecnica delle Marche, Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I GM Lancisi G Salesi di Ancona, Medical Oncology Unit, Ancona, Italy
Expert Opin Pharmacother 10:2245-58. 2009
..This review discusses the role of neoadjuvant chemoradiotherapy regimens used in the standard combined modality treatment programs for rectal cancer and focuses on the ongoing research to improve these regimens...